Australian telehealth and DTC health platforms.

In Australia, advertising a Schedule 4 prescription medicine to consumers is prohibited outright. The bright line for the entire telehealth and DTC health category sits one section deep into the Therapeutic Goods Act 1989, and almost every commercially viable funnel for men's health, women's health, weight management and chronic care has to be built on the consultation-led side of it.

A telehealth or DTC health platform answers to a stack of authorities at once, with the Commonwealth substance regulator at the top.

The dominant frame is the Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA). Section 42DLB is the civil-penalty operative provision and section 42DL its criminal counterpart. Together they prohibit advertising any therapeutic good containing a Schedule 4 (prescription-only) or Schedule 8 substance to the public, including indirect references — naming the medicine, picturing it, or pointing to it through a condition-led claim is enough to engage the section.

The substantive code beneath the Act is the Therapeutic Goods (Therapeutic Goods Advertising Code) Instrument 2021, in force since 1 January 2022. It governs mandatory statements, prohibited representations, testimonials, endorsements and undue alarm. The TGA's social media advertising guidance overlays the Code on Meta, TikTok, YouTube and creator content.

Where prescribers feature, the Health Practitioner Regulation National Law, administered by the Australian Health Practitioner Regulation Agency (AHPRA) and the Medical Board of Australia, governs their conduct, with section 133 capturing testimonials and unreasonable expectations of beneficial treatment in any health-service advertising.

Patient information sits within the Privacy Act 1988 and the Australian Privacy Principles, regulated by the Office of the Australian Information Commissioner, with mandatory notification of eligible data breaches. Non-substance trade conduct — pricing, comparative claims, subscription terms — falls within the Australian Consumer Law, enforced by the ACCC. Meta's Health and Wellness ad standard and Google's restricted-vertical review for telehealth sit downstream as platform-level constraints — not regulators, but in practice they decide whether a campaign serves at all.

The penalties are not theoretical. The maximum civil penalty under section 42DLB is 5,000 penalty units for an individual and 50,000 penalty units for a body corporate — at the current penalty-unit value of $330 (since 7 November 2024), $1,650,000 and $16,500,000 per breach respectively. Each non-compliant advertisement is a separate matter.

Enforcement against the category is now routine. In July 2024 the TGA fined four businesses and three individuals a combined $319,260 across 21 infringement notices for unlawful advertising of weight-loss and erectile-dysfunction medicines including Ozempic, Saxenda and Viagra. Midnight Health Pty Ltd, operating Youly, Stagger and hub.health, paid $198,000 across ten infringement notices in September 2025 for advertising semaglutide and tirzepatide between June 2024 and January 2025, and gave the TGA a one-year enforceable undertaking. In January 2026, Prime Medic Group and an associated individual paid $19,800 and $3,960 respectively for advertising Ozempic and Mounjaro.

The TGA requested removal of more than 13,700 unlawful advertisements from digital platforms in 2024–25, and from 1 January 2026 weight-loss medications and erectile-dysfunction medications are both on its 12-area priority focus list for 2026–27. The category is under active surveillance.

Two failure modes recur, and the notice arrives at the platform's registered office, not the agency's.

The generalist who imports a US playbook. An e-com agency built for purchase-intent retargeting ports US-style DTC creative directly into the AU market: substance-named landing pages, the medicine pictured in carousels, before/after weight-loss imagery, condition-forward Meta hooks. Each is a section 42DLB breach on the first impression, and TGA social-media surveillance picks them up at scale. The agency invoices and moves on; the platform inherits the notice, the undertaking and the public media release.

The cautious agency that overcorrects to nothing. Faced with a regime they cannot read, the agency strips substance, condition and outcome out of the work until the funnel is "speak to a clinician about your health" — defensible, and commercially inert. CAC blows out, payback collapses, the founder burns runway, and the agency concludes telehealth marketing does not work. The truth is the agency could not see what was permitted on the consultation-led side of the line.

You may recognise one of these from past engagements.

The line between substance-side and consultation-led advertising is the bright line for the whole category. Once a brand finds the durable side of it — the side that survives a TGA social-media audit, the next Code revision and a Meta restricted-vertical review in the same quarter — the work compounds. The same creative system carries through audits, code clarifications and platform reviews without being redrawn. Most teams patch their way to that side, ad by ad, retroactively. The depth is in briefing the work from the spec rather than retrofitting to it. The constraint filters out the competitors who cannot operate inside it, which is precisely what makes the inside of the regime defensible. Compliance, treated as a posture rather than a tax, becomes positioning.

Regimen is built for regulated Australian professional services. Compliance review runs on every piece of work we ship — copy, creative, landing pages, paid media, organic, prescriber-side and consumer-side — against the current Therapeutic Goods Advertising Code, sections 42DL and 42DLB of the Act, the TGA social-media guidance, AHPRA section 133 where prescribers feature, the Australian Consumer Law and the Privacy Act. We know the seams: where the Code's testimonial and endorsement rules collide with creator content, where a condition-led hook tips into a substance-side reference, and where platform category restrictions track and diverge from TGA priorities.

If you run a telehealth platform or a DTC health brand and you want marketing that converts inside the rules rather than around them, book a 30-minute discovery call. We will tell you, on the call, whether your current advertising would survive a TGA audit.